Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Development of major adverse cardiovascular events, which impact cardiovascular prognosis after coronary angioplasty, are influenced by the extent of coronary damage and vascular repair. The use of novel coronary cellular and soluble biomarkers, reactive to vascular damage and repair, are useful to predict the development of MACEs and prognosis.

Abstract

Major adverse cardiovascular events (MACEs) negatively impact the cardiovascular prognosis of patients undergoing coronary angioplasty due to coronary ischemic injury. The extent of coronary damage and the mechanisms of vascular repair are factors influencing the future development of MACEs. Intrinsic vascular features like the plaque characteristics and coronary artery complexity have demonstrated prognostic information for MACEs. However, the use of intracoronary circulating biomarkers has been postulated as a convenient method for the early identification and prognosis of MACEs, as they more closely reflect dynamic mechanisms involving coronary damage and repair. Determination of coronary circulating biomarkers during angioplasty, such as the number of subpopulations of mononuclear progenitor cells (MPCs) as well as the concentration of soluble molecules reflecting inflammation, cell adhesion, and repair, allows for assessment of future developments and the prognosis of MACEs 6 months post coronary angioplasty. This method is highlighted by its translational nature and better performance than peripheral blood circulating biomarkers regarding prediction of MACEs and its effect on the cardiovascular prognosis, which may be applied for risk stratification of patients with coronary artery disease undergoing angioplasty.

Introduction

Coronary angioplasty and stenting represent a salvage procedure for patients with coronary artery disease (CAD). However, major adverse cardiovascular events (MACEs), including cardiovascular death, myocardial infarction, coronary restenosis, and episodes of angina or decompensate heart failure, may occur months after coronary intervention, prompting unscheduled visits to the hospital. MACEs are common worldwide and their morbi-mortality is high1.

Coronary ischemic injury induces early vascular response and reparative mechanisms involving mobilization of MPCs due to their differentiation ability and/or angio-reparati....

Protocol

This protocol meets the institutional guidelines from the human research Ethics Committee.

1. Coronary Angiography, Ultrasound, and Blood Sampling

  1. Request baseline clinical and demographic information before coronary intervention. Collect the individual's data: age, sex, current smoking status, body mass index (BMI), high blood pressure, dyslipidemia, diabetes mellitus, medications, and the indication for current coronary angiography.
  2. Perform coronary angiography thro.......

Representative Results

Coronary, venous sinus, and peripheral blood were collected from 52 patients that underwent coronary angiography (Figure 1) and showed a high prevalence of hypertension and dyslipidemia. At the clinical follow-up, 11 (21.1%) MACEs occurred 6 months after coronary angiography: death (n = 1), angina requiring hospital attendance (n = 6), myocardial infarction (n = 2), and/or evidence of heart failure (n = 4).

Discussion

Blood collection from the affected coronary artery may be difficult. Sometimes, the coronary artery is barely accessible. In this case, sampling from the venous sinus may be an alternative. We performed validation tests comparing circulating biomarkers in coronary artery vs. venous sinus, with no significant differences. However, the performance of circulating biomarkers was validated only for coronary sampling. Therefore, the performance of biomarkers obtained from the venous sinus remains to be explored.

Acknowledgements

The authors thank the support of Institutional Program E015; and Fondo Sectorial FOSSIS-CONACYT, SALUD-2014-1-233947.

....

Materials

NameCompanyCatalog NumberComments
BSARoche10735086001Bovine Serum Albumin (BSA) as a buffering agent, stabilizer, standard and for blending.
Calibration BeadsMiltenyi Biotec / MACS#130-093-607MACQuant calibration beads are supplied in aqueous solution containing 0.05% sodium azide. 3.5 ml for up to 100 tests
CD133/1 (AC133)-PEMilteny Biotec / MACS#130-080-801Antibody conjugated to R-Phycoerythrin in PBS/EDTA buffer
CD184 (CXCR4)-PE-VIO770Miltenyi Biotec / MACS#130-103-798Monoclonal, Isotype recombinant human IgG1, conjugated
CD309 (VEGFR-2/KDR)-APCMiltenyi Biotec / MACS#130-093-601Antibody conjugated to R-Phycoerythrin in PBS/EDTA buffer
CD34-FITCMiltenyi Biotec / MACS#130-081-001The monoclonal antibody clone AC136 detecs a class III epitope of the CD34
CD45- VioBlueMiltenyi Biotec / MACS#130-092-880Monoclonal CD45 Antibody, human conjugated
Conical TubesThermo SCIENTIFIC#33965115ml conical centrifuge tubes
Cytometry TubesFALCON Corning Brand#3520525 mL Polystyrene Round-Bottom Tube. 12x75 style. Sterile.
EDTABIO-RAD#161-0729Heavy metals, (as Pb) <10ppm, Fe <0.01%, As <1ppm, Insolubles <0.005%
Improved NeubauerWithout brandWithout catalog numberHemocytometer for cell counting. (range 0.1000mm, 0.0025mm2)
K2 EDTA Blood Collection TubesBD Vacutainer#367863Lilac plastic vacutainer tube (K2E) 10.8mg, 6 mL.
LymphoprepStemcell Technologies01-63-12-002-ASterile and checked on the presence of endotoxins. Density: 1.077±0.001g/mL
ParaformaldehydeSIGMA-ALDRICH#SZBF0920VFixation of biological samples, (powder, 95%)
Pipette Transfer 1,3mLCRM GlobePF1016, PF1015The transfer pipette is a tool that facilitates liquid transfer with greater accuracy.
Test TubesKIMBLE CHASE45060 13100Heat-resistant test tubes. SIZE/CAP 13 x 100 mm

References

  1. Cassar, A., Holmes, D. R., Rihal, C. S., Gersh, B. J. Chronic coronary artery disease: diagnosis and management. Mayo Clinic Proceedings. 84 (12), 1130-1146 (2009).
  2. Regueiro, A., et al.

Explore More Articles

Coronary Progenitor CellsSoluble BiomarkersCardiovascular PrognosisCoronary AngioplastyIschemic SettingsRecurrent Limb IschemiaStrokeFlow CytometryDensity Gradient MediumCell SeparationCell CountingAntibody Staining

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved